|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy of early treatment with infliximab in pediatric Crohn’s disease显示文摘AIM: To investigate the effectiveness of early infliximab use for induction and maintenance therapy in pediatric Crohn’s disease. METHODS: We performed a retrospective chart review of 36 patients with Crohn’s disease. Ten patients (group A) were treated with mesalamine after induction therapy with oral prednisolone, and 13 patients (group B) were treated with azathioprine after induction therapy with oral prednisolone. Thirteen patients (group C) received infliximab and azathioprine for induction and maintenance therapy for the first year, and were treated with azathioprine after 1 year. All patients were followed for at least 24 mo. Efficacy was determined by the relapse rate using the pediatric Crohn’s disease activity index score in each group at 12 and 24 mo. RESULTS: At the 1 year follow-up, the relapse ratee, Mi Jin Kim, Hae Jeong Lee, Yon Ho Choe (23.1%, 3 of 13 patients) in group C was lower than that (61.5%, 8 of 13 patients) in group B (P = 0.047). At the 2 years follow-up, the relapse rate (38.5%, 5 of 13 patients) in group C was lower than that (76.9%, 10 of 13 patients) in group B (P = 0.047). Adverse events in group C were fewer than in groups A and B. CONCLUSION: Early induction with infliximab at diagnosis, known as 'top-down' therapy, was effective for reducing the relapse rate compared to conventional therapies for at least 2 years. | Jong Seung Lee Jee Hyun Lee Ji Hyuk Lee Hye Jin Lee Mi Jin Kim Hae Jeong Lee Yon Ho Choe | 2010 | World Journal of Gastroenterology2010，16，14： | 10 |
| 2 | Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus显示文摘 | Yun-Mi Song Joohon Sung Soonha Yang Yon Ho Choe Yun Sil Chang Won Soon Park | 2007 | European Journal of Pediatrics2007，，8： | 1 |
| 3 | Histopathology and expression of Ki-67 and cyclooxygenase-2 in childhood Helicobacter pylori gastritis显示文摘 | Kyung Mo Kim Young Lyun Oh Jae Sung Ko Yon Ho Choe Jeong Kee Seo | 2004 | Journal of Gastroenterology2004，，3： | 1 |
| 4 | How has the disease course of pediatric ulcerative colitis changed throughout the biologics era?A comparison with the IBSEN study显示文摘BACKGROUND In Korea,infliximab was approved for use in children with ulcerative colitis(UC)in October 2012.AIM To compare the clinical course of UC before and after the introduction of biological agents,and to compare with the IBSEN study.METHODS Patients under 18 years of age,who were diagnosed with UC and followed from January 2003 to October 2020,were included in the study.Group A(n=48)was followed for at least 2 years between January 2003 and October 2012,and Group B(n=62)was followed for at least 2 years between November 2012 and October 2020.We compared endoscopic remission,drug composition,relapse rate,steroidfree period,and the quality of life of each group.We plotted the clinical course of the included patients using the pediatric UC activity index score,and compared our patients with those in the IBSEN study.RESULTS After 2 years of treatment,colonoscopy evaluation revealed different outcomes in the two treatment groups.Remission was confirmed in 14 patients(29.2%)of Group A,and in 31 patients(50.0%)of Group B(P<0.012).The median cumulative corticosteroid-free period was 3.0 years in Group A and 4.4 years in Group B.Steroid-free period of Group B was significantly longer than that of Group A(P<0.001).There was a statistically significant difference between the two groups in evaluation of the relapse rate during the observation period(P<0.001).The plotted clinical course graphs of Group A showed similar proportions to the graphs in the IBSEN study.However,in Group B,the proportion of patients corresponding to curve 1(remission or mild severity after initial high activity)was high at 76%(47/62).CONCLUSION The incidence of relapse has decreased and the steroid-free period has increased after the introduction of the biological agent.The clinical course also showed a different pattern from that of IBSEN study.The active use of biological agents may change the long-term disease course in moderate to severe pediatric UC. | Yiyoung Kwon Eun Sil Kim Yon Ho Choe Mi Jin Kim | 2022 | World Journal of Gastroenterology2022，28，28： | 1 |
| 5 | Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus显示文摘 | Yun-Mi Song Joohon Sung Soonha Yang Yon Ho Choe Yun Sil Chang Won Soon Park | 2007 | European Journal of Pediatrics2007，，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员